Capecitabine Tolerance of EU vs US Patients

Share this content:
One theory about differing capecitabine tolerance in patient populations relates to folic acid content in food.
One theory about differing capecitabine tolerance in patient populations relates to folic acid content in food.

Why are European patients better able to tolerate high doses of capecitabine than US patients?

This is a really interesting question. One theory relates to folic acid content in food. Capecitabine (Xeloda) is an oral prodrug of fluorouracil (5-FU). 5-FU is frequently given with leucovorin, which is a reduced form of folic acid. This increases the efficacy — and toxicity — of 5-FU.

In the United States, many foods are enriched with folic acid. This exposure to more folic acid may explain why patients in the United States experience more adverse effects from capecitabine than their counterparts elsewhere.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs